OT-551 | CAS#627085-11-4 | CAS#627085-15-8 | NF-κB inhibitor

MedKoo Cat#: 529512 | Name: OT-551

Description:

WARNING: This product is for research use only, not for human or veterinary use.

OT-551 is a NF-κB inhibitor potentially for the treatment of cataracts and age-related macular degeneration.

Chemical Structure

OT-551

CAS#627085-11-4 (free base)

Theoretical Analysis

MedKoo Cat#: 529512

Name: OT-551

CAS#: 627085-11-4 (free base)

Chemical Formula: C13H23NO3

Exact Mass:

Molecular Weight: 241.33

Elemental Analysis: C, 64.70; H, 9.61; N, 5.80; O, 19.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

627085-15-8 (HCl) 627085-11-4 (free base)

Synonym

OT-551; CPC-551; OT 551; CPC 551; OT551; CPC551

IUPAC/Chemical Name

1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl cyclopropanecarboxylate

InChi Key

ZWEXEKJLDHNLLA-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H23NO3/c1-12(2)7-10(8-13(3,4)14(12)16)17-11(15)9-5-6-9/h9-10,16H,5-8H2,1-4H3

SMILES Code

O=C(C1CC1)OC2CC(C)(C)N(O)C(C)(C)C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 241.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, Cukras C, Chew EY, Sadda SR, Ferris FL. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6131-9. doi: 10.1167/iovs.10-5637. PubMed PMID: 20574018; PubMed Central PMCID: PMC3055748. 2: Tanito M, Li F, Anderson RE. Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats. Exp Eye Res. 2010 Jul;91(1):111-4. doi: 10.1016/j.exer.2010.04.012. PubMed PMID: 20434439; PubMed Central PMCID: PMC3175818. 3: Zarling JA, Brunt VE, Vallerga AK, Li W, Tao A, Zarling DA, Minson CT. Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. doi: 10.3389/fgene.2015.00325. Review. PubMed PMID: 26594225; PubMed Central PMCID: PMC4635221. 4: Tanito M, Li F, Elliott MH, Dittmar M, Anderson RE. Protective effect of TEMPOL derivatives against light-induced retinal damage in rats. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1900-5. PubMed PMID: 17389526. 5: Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Sep;6(5):565-79. doi: 10.1586/17512433.2013.829645. Review. PubMed PMID: 23971874. 6: Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica. 2009;223(6):401-10. doi: 10.1159/000228926. Review. PubMed PMID: 19622904.